reproxalap topical (ADX-102 topical)
/ Aldeyra
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
June 18, 2024
Porcine deltacoronavirus nonstructural protein 2 inhibits type I and III IFN production by targeting STING for degradation.
(PubMed, Vet Res)
- "Furthermore, K150 and K236 of pSTING were identified as crucial residues for nsp2-mediated ubiquitination and degradation. In summary, our findings provide a basis for elucidating the immune evasion mechanism of PDCoV and will contribute to the development of targets for anti-coronavirus drugs."
Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Targeted Protein Degradation • KEAP1 • STING
May 31, 2023
Genomes of the autonomous parvovirus minute virus of mice induce replication stress through RPA exhaustion.
(PubMed, PLoS Pathog)
- "Ectopically expressed viral non-structural proteins NS1 and NS2 are sufficient to cause host-cell replication stress, as is the presence of UV-inactivated non-replicative MVM genomes...Overexpressing RPA in host cells prior to UV-MVM infection rescues DNA fiber lengths and increases MVM replication, confirming that MVM genomes deplete RPA stores to cause replication stress. Together, these results indicate that parvovirus genomes induce replication stress through RPA exhaustion, rendering the host genome vulnerable to additional DNA breaks."
Journal • Preclinical • Infectious Disease • RPA1
November 09, 2020
RESET Trial - Part 1 (Followed by Reset Trial - Part 2) - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)
(clinicaltrials.gov)
- P3; N=11; Completed; Sponsor: Aldeyra Therapeutics, Inc.; Suspended ➔ Completed; N=39 ➔ 11; Trial completion date: Dec 2020 ➔ Jan 2020; Trial primary completion date: Dec 2020 ➔ Jan 2020
Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Complement-mediated Rare Disorders
March 19, 2020
RESET Trial - Part 1 (Followed by Reset Trial - Part 2) - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)
(clinicaltrials.gov)
- P3; N=39; Suspended; Sponsor: Aldeyra Therapeutics, Inc.; Recruiting ➔ Suspended
Clinical • Trial suspension
1 to 4
Of
4
Go to page
1